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Cellular proliferation and macrophage influx precede interstitial fibro.
sis in cyclosporine nephrotoxicity. Chronic cyclosporine (CsA) nephro-
toxicity is a major complication of solid organ transplantation, and is
characterized histologically by striped tubulointerstitial fibrosis, tubular
atrophy, and hyalinization of the afferent arteriole, a highly specific finding
in cyclosponne injuly. The salt-depleted rat model of chronic cyclosporine
nephropathy mimics these lesions in humans. We conducted sequential
studies of this model in groups of pair fed rats (N = 6) treated with CsA(15 mg/kg, s.q.) or an equivalent dose of olive oil. Proliferation of tubular
and interstitial cells was documented early in the medulla by day 5 (3.2
2.1 vs. 0.81 0.4 cellstHPF in CsA vs. control, P < 0.02),and was maximal
in areas of interstitial fibrosis by day 35 (7.9 3.7 vs. 0.52 0.2 cells/HPF
in CsA vs. control, P < 0.005). The interstitial fibrosis was associated with
a significant macrophage influx by day 35 (13.9 3.5 vs. 1.5 0.32
cells/HPF, CsA vs. control, P < 0.005), which correlated with increased
cortical tubular staining for the macrophage adhesion protein, osteopon-
tin. Elevated serum creatinine correlated with interstitial fibrosis at day 35
(0.85 0.11 vs. 0.40 0.03 mg/dl Cr, CsA vs. control, P < 0.005) by linear
regression (r = 0.9, P < 0.05). Medullary proliferation and interstitial
fibrosis correlated with decreased tubular concentrating ability, and higher
urinary volume. Cortical interstitial fibrosis was maximal at day 35 and was
associated with an increase in type I and type IV collagen deposition, while
tubular injury was associated with increased vimentin expression. Tubular
interstitial cells also expressed increased vimentin early in the medulla
(day 10) and later in the cortex. Both groups remained normotensive
despite significantly elevated juxtaglomerular (JG) apparatus renin ex-
pression in CsA treated animals, implicating the intrarenal-renal renin-
angiotensin system in this disease. We conclude that cyclosporine neph-
rotoxicity is associated with early tubular and interstitial cell proliferation,
and a significant macrophage influx that precedes the development of
cortical interstitial fibrosis and afferent arteriolar hyalinosis. These early
cellular changes correlate with functional abnormalities including de-
creased creatinine clearance (Car) and decreased medullary concentrating
ability, which stabilized despite progressive fibrosis. These cellular events
may be important in the pathogenesis of chronic CsA nephrotoxicity.
Since its introduction in 1976 [1], cyclosporine A (CsA) has
improved the survival of solid organ transplants markedly, and has
also found utility in the treatment of autoinimune diseases.
However, the benefits of CsA therapy have been potentially offset
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by the occurrence of significant nephrotoxicity, both acute and
chronic [2, 3]. Although acute CsA nephrotoxicity is reversible,
chronic CsA nephrotoxicity may progress to an irreversible renal
lesion characterized by striped interstitial fibrosis, tubular atrophy
and the pathognomonic lesion of hyalinosis of afferent arterioles
[4, 5]. Chronic CsA nephropathy has been described in both renal
and non-renal allograft recipients, as well as in patients being
treated with CsA for autoimmune disease, and progression to
end-stage renal disease has been well documented in some
patients [6—11].
The lesion of chronic CsA nephropathy has been difficult to
reproduce in animals. Thus, the pathogenesis of this type of
CsA-induced renal injury has been difficult to study. Recently, an
animal model of chronic CsA nephrotoxicity has been developed
using salt depletion as a stimulus to accelerate the long term
effects of CsA treatment [12].
In the present study we have utilized this new model of CsA
nephrotoxicity in the salt-depleted rat with several features which
resemble the human lesion in an attempt to clarify the pathogen-
esis of CsA nephropathy. In this model we can assess sequentially
changes in renal cell phenotype, and correlate these cellular
events with the onset of renal functional and structural abnormal-
ities. Our findings document an early phase of CsA-induced renal
cell proliferation and macrophage infiltration that may be central
to the later development of interstitial fibrosis and progressive
disease.
Methods
Adult, male Sprague-Dawley rats (Charles River, Wilmington,
MA, USA), 225 to 250 g, were housed in individual cages in a
temperature and light controlled environment, and received a low
salt diet (0.05% sodium, Teklad, Premier, WI, USA), with water
ad libitum. After one week on the low salt diet, weight matched
pairs of rats were randomly assigned to receive daily subcutaneous
injections of CsA (Sandoz Research Institute, East Hanover, NJ,
USA), or an identical volume of the vehicle olive oil as a control.
Control rats were pair fed the exact amount of food consumed the
day before by the CsA-treated rats. Animals were divided into two
groups of 24 CsA-treated and 24 control rats. Six rats from each
group were studied at days 5, 10, 26 and 35. Body weight was
recorded daily. Tail cuff blood pressures were measured at the end
of each treatment period, and rats were placed in metabolic cages
439
•; ;1 iat rTtr - - -—440 Younget al: Cellular events in CsA nephropathy
Fig. 1. PAS staining demonstrates progression of interstitial fibrosis in CsA treated animals. On day five (A) there are minimal intersitital abnormalities
(200x). By day 10 (B) there is mild tubular dilitation and interstitial thickening (200x). On day 26 (C) advanced tubular dilation, interstitial thickening,
and tubular casts with calcifications are seen with normal glomeruli (200X). By day 35 (D) there is progressive, striped interstitial fibrosis (50X).
for a 24-hour urine collection. The following day animals were
anesthetized with Nembutal, a blood sample was obtained, and
both kidneys were collected for histologic evaluation.
Morphology
Renal tissue at sacrifice was fixed in methyl Carnoy's solution
and embedded in paraffin. Four micron sections were stained with
periodic acid and Schifs reagent (PAS), and counterstained with
hematoxylin. Tissue samples were evaluated for interstitial fibro-
sis, arteriolar hyalinosis, tubular dilatation, calcification and cast
formation. Fibrosis was scored semiquantitatively by an observer
blinded to the origin of the biopsy, who examined tubulointersti-
tial fields adjacent to an arbitrary glomerulus at 400X, using a 10
mm x 10 mm grid for reference. A minimum of 20 fields were
assessed per tissue sample. The following semiquantitative score
was used:
0 = normal interstitium and tubules;
1 + minimal fibrosis with slight disruption and mild intersti-
tial thickening between tubules;
2+ = mild to moderate fibrosis with mild interstitial thickening
between tubules;
3+ = moderate fibrosis with interstitial thickening between
tubules, minimal tubular dilatation;
4+ = severe fibrosis with tubular dilatation, significant inter-
stitial thickening between tubules and thickening of the tubular
basement membrane.
Immunohistochemisty
Tissue was sectioned (4 m) and stained using standard immu-
noperoxidase procedures described elsewhere [13, 15, 16]. The
following monoclonal (or polyclonal) antibodies were used as
described previously [13—15]:
• 19A2, against the proliferating cell nuclear antigen (PCNA)
(Coulter, Hialeah, FL, USA) expressed by actively proliferating
cells [17];
• ED-i (Bioproducts for Science, Indianapolis, IN, USA),
expressed on macrophages/monocytes and dendritic cells [13];
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Functional studies
Urinary and plasma sodium were measured by flame photom-
eter (Instrumentation Laboratories, Lexington, MA, USA). Uri-
nary and plasma osmolality were measured by freezing point
depression (Osmette A; Precision Systems Inc., Natick, MA,
USA). Urinary and serum creatinine, urinary protein (Uprot),
urinary alanine aminopeptidase (AAP) and urinary N-acetyl
f3-D-glucosaminidase (NAG) were measured by a Cobas autoana-
lyzer (Roche Diagnostics, Division. Hoffman-La Roche Inc.,
Nutley, NJ, USA). CsA blood levels were determined in whole
blood by a specific radioimmunoassay (Incstar Corp., Stillwater,
MN, USA). The clearance of creatinine (Car), fractional excretion
of sodium (FENa) and free water reabsorption (TcW) were
calculated using standard formulas, Blood pressure was measured
at all time points in animals by tail cuff.
Statistics
Results are presented as the mean standard error. Compar-
25 30 35 isons between CsA and placebo animals were done by two-tailed
unpaired Student's t-test or Mann Whitney test, as appropriate
scale of 0 to 4+) in [24]. Statistical significance was defined as P < 0.05.
Histologic changes
• P1-i, murine monoclonal antibody against rat platelets (gift of
W.W. Baker, Groning, Netherlands) [18];
• OX-22, specific for the high molecular weight common
leukocyte antigen on B and some T lymphocytes [13];
• RP-3, a murine monoclonal antibody against rat neutrophils
(gift of F. Sendo, Yamagata, Japan) [19];
• SM-i, a murine monoclonal antibody to an NH2-terminal
synthetic decapeptide of alpha smooth muscle actin (gift of G.
Gabbiani, Geneva, Switzerland) [20];
• the IgG fraction of polyclonal guinea pig anti-rat type I
collagen (gift of L. Iruela-Arispe and H. Sage, Seattle, WA, USA)
[14];
• polyclonal goat anti-mouse IgG fraction against type IV
collagen (Southern Biotech, Birmingham, AL, USA) [14];
• monoclonal mouse anti-rat IgG fraction against vimentin
(Dako Corp., Santa Monica, CA, USA) [20];
• F37.2D12, a murine monoclonal against human renin (gift of
M. Laprade, Sanofi Recherche, Montpelier, France) [21]; and
• MPIIIB1O, a murine monoclonal against rat osteopontin
(obtained from the Developmental Studies Hybridoma Bank
maintained by the Department of Pharmacology and Molecular
Sciences, Johns Hopkins University School of Medicine, Balti-
more, MD, and the Department of Biological Sciences, University
of Iowa, Iowa City, IA, USA) [22, 23].
Each tissue sample was viewed and scored by an observer
blinded to the treatment received. Quantitation was performed at
400X magnification using a 10 mm x 10 mm grid within the
microscope eyepiece to demarcate at least 20 tubulointerstitial
fields exclusive of glomeruli. Renin was semiquantitatively esti-
mated by counting the percentage of glomeruli with positive
juxtaglomerular (JG) apparatus staining, with a minimum of 20
glomeruli assessed, as described previously [22]. Renal tissue
samples were divided into medullary and cortical areas for
quantitation with various stains.
Cyclosporine treated rats had characteristic morphologic find-
ings which were reminiscent of the human lesion. There was a
mononuclear cell inifitrate by dayS and mild tubular dilatation by
day 10. There were juxtamedullaiy tubular casts, some with
calcifications, and early striped cortical fibrosis by day 26, and
finally severe striped interstitial fibrosis with a progressive inflam-
matory cell infiltrate associated with thickening of tubular base-
ment membranes and Bowman's capsule by day 35 (Fig. 1). There
was an early significant increase in medullary fibrosis by day 10
that continued to day 35. Significant tubular dilatation with
thickening of tubular basement membranes (TBM), occurred in
the areas of cortical striped interstitial fibrosis. This was in marked
contrast to adjacent normal tubules in neighboring areas of the
cortex. A mild medullary interstitial widening was also present
and maximal at day 35. Vehicle control animals showed no
medullary or cortical interstitial fibrosis, interstitial infiltrate,
tubular dilatation, tubular casts or cast calcification throughout
the 35 days of olive oil treatment.
Cyclosporine treated animals also showed progressive hyalino-
sis of select hilar arterioles initially evident by day 10, similar to
the cyclosporine arteriolopathy seen in humans. These vascular
lesions are the subject of a separate report [B. Young, companion
manuscript; 25].
The interstitial fibrosis was characterized by an early loss of
tubular segments, with other tubules showing dilatation with
vacuolization, and with increased interstitial matrix deposition.
There was focal disruption of TBM in some areas of interstitial
infiltrate with loss of tubular definition. Fibrosis was quantitated
on a scale of 1 to 4+ with 4+ indicating diffuse fibrosis. The
maximum fibrosis score of 2.2 occurred at day 35, which was
indicative of the striped intermittent nature of the disease (Fig. 2).
CsA treated animals demonstrated that the interstitial fibrosis
observed was composed in part of de novo expression of collagen
type I and increased expression of collagen type IV. The distri-
bution of these collagens differed somewhat; collagen type I was
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Fig. 3. Type I collagen deposition is increased in an interstitial distribution in CsA -treated animals (A) compared to controls (B) (200X). Type IV collagen
is also increased in GsA-treated animals (B) compared to controls (E), but is most striking in tubular basement membranes and Bowman's capsule
(200x). Vimentin staining is also increased in tubular epithelial cells in a CsA-treated animal (C) compared to a vehicle control (F) (bOX).
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increased in the areas of interstitial fibrosis both in the medulla
and the cortex and mildly around Bowman's capsule starting at
day 26, while collagen type IV expression was also increased in
areas of tubulointerstitial fibrosis, but was more pronounced
around the thickened tubular basement membranes and around
the thickened basement membranes of Bowman's capsule (Fig. 3).
Collagen type I was only expressed around blood vessels in control
animals, and did not increase with time. It was never increased in
the interstitium of control animals. Collagen type IV was present
in the TBM and Bowman's capsule of control animals, but was not
expressed in the interstitium. Expression of collagen type IV did
not change with time in control animals.
Alpha-smooth muscle actin was present in arterioles and pro-
gressively increased in the vasculature (vasa recta and arterioles)
in CsA treated animals throughout the study. There was minimal
increase of a-actin in interstitial cells at day 35 in CsA treated
animals. Control animals showed positive staining for actin in
arteries and arterioles, but minimal to no staining in the vasa recta
throughout the study.
Injured cortical proximal tubular cells also stained positively
with vimentin, a marker of regenerating tubular cells [25]. There
was a progressive, focal increase in vimentin expression, starting
at day 10, in atrophic and dilated tubules with mild expression in
cortical interstitial cells. Expression increased in tubules and
interstitial cells as cortical interstitial fibrosis progressed (day 35)
which seemed to correlate with the amount of tubular injury (Fig.
3). Expression of vimentin was also present early in the intersti-
tium of the medulla (day 10), and increased as medullary fibrosis
progressed. Staining for vimentin in control animals was positive
in the glomeruli, the arterioles, and vasa recta in the medulla.
Proliferation
Proliferation was assessed by quantitation of cells that stained
positively for the PCNA. A biphasic response was observed.
Increased proliferation was observed in tubular and interstitial
cells in the medulla early (day 5 to 10), while tubular and
interstitial cells in the areas of interstitial fibrosis showed a
progressive increase in proliferation which was maximal on day 26
with a slight decrease by day 35 (Fig. 4). It was difficult to
distinguish between tubular and interstitial cells in focal areas of
the biopsies where there was substantial inflammatory cell influx
and tubular disruption, but proliferating cells were clearly both
tubular as well as interstitial in origin. Assessment of the total
biopsy indicated that proliferation was maximal on day 35 (7.93
3.69 vs. 0.52 0.19 PCNA positive cells/HPF, CsA vs. control, P
<0.05).
Influx of circulating cells
CsA treated animals showed a striking influx of ED-i positive
cells as early as day five, and infiltrating cells increased steadily in
the areas of interstitial fibrosis. Macrophage influx occurred early
in both the medulla and cortex. Macrophages were observed near
and within the lumens of vascular bundles within the medulla in a
diffuse pattern. This was in contrast to the focal increase in
macrophage influx around cortical tubular cells, and within the
interstitium. Interstitial macrophages occasionally assumed a pen-
glomerular distribution. There was further macrophage localiza-
tion in areas of interstitial fibrosis by days 26 and 35 (Fig. 5).
Macrophages appeared to remain peritubular within the intersti-
tium with no macrophages observed within tubular lumens.
Macrophage staining also increased in glomeruli by days 26 and
35. Periglomerular macrophage staining remained focal and was
maximal in areas of interstitial fibrosis. Vehicle control animals
showed minimal staining for ED-i positive cells in the medulla
and cortex throughout the study.
Staining for neutrophils was minimal, while staining for the
common leukocyte antigen on B and some T cells identified only
small, focal infiltrates of cells within the interstitium that were
maximal at day 35, Staining for platelets was minimal (data not
shown).
Renin
Biopsies stained with the monoclonal antibody to human renin
showed that both cyclosponine treated and control salt depleted
animals had an increased percentage of glomeruli with juxtaglo-
merular apparatus staining for renin (66.9% 8.3 and 41.5%
4.9, respectively, P < 0.005, average of all time points) (Fig. 6),
compared to normal values of 30% [221. Moreover, CsA treated
animals had significantly greater glomerular renin staining com-
pared to controls at every time point. There was also a significant
hypertrophy of the juxtaglomerular .(JG) apparatus in cyclospo-
rine treated animals, that was characterized by increased cyto-
plasm and increased cytoplasmic expression of renin in tubular
cells that were adjacent to the hilum of glomeruli. This increased
expression of renin occurred in the setting of normal blood
pressures in both CsA treated rats and controls (Table 4). Renin
expression appeared to be diffuse in CsA treated animals, and did
not follow a striped distribution.
Osteopontin expression
Osteopontin was normally expressed in the medulla and in rare
distal tubules of the cortex of control animals in either a diffuse or
basolateral fashion as reported by several groups [23, 26, 27].
However, osteopontin was found to be significantly increased in
dilated tubular cells within the cortex of CsA treated rats in the
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Fig. 4. Time course of prolifrration of tubular and interstitial cells assessed
by PCNA staining in CsA -treated animals compared to vehicle-treated
controls.
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Fig. 6. Graph of renin staining expressed as the percentage of glomeruli with
positive JG-apparatus staining in CsA -treated versus vehicle-treated control
animals. Salt depletion increased renin secretion above normal (30%) in
controls, but CsA-treated animals had a further elevation in renin
expression compared to controls at every time point.
areas of interstitial fibrosis (Fig. 7). Osteopontin expression was
seen as early as five days in some biopsies in areas of slight tubular
dilatation and infiltration, with maximal expression by days 26 and
35. There was also a slight increase in Bowman's capsule. Os-
teopontin showed a striking luminal distribution and appeared to
surround sloughed tubular cells in severe areas of interstitial
fibrosis. Osteopontin was also present in juxtamedullary areas of
calcification (Fig. 8) and tubular obstruction from cast formation.
There was also a striking co-localization with macrophages in the
areas of cortical interstitial fibrosis.
20 Physiologic studies
Body weight and blood pressure were similar in placebo and
CsA-treated rats at all time points (Table 4). There was a
progressive increase in CsA whole blood levels in CsA-treated
animals: 2093 127 ng/ml at day 5, 2821 262 ng/ml at day 10,
6223 116 ngfml at day 26 and 6199 806 ng/ml at day 35.
CsA induced a significant increase in serum creatinine (Sr)
and a significant decrease in Cr at days 10, 26 and 35 (Table 1).0 10 These changes were progressive until day 26 where stabilization
occurred. There was no proteinuria in CsA treated or placebo
animals. In fact, CsA treated animals had significantly less pro-
teinuria than placebo rats at days 10 and 26 (Table 1). The rise in
creatinine correlated with progressive interstitial fibrosis by linear
W regression (r = 0.90, P < 0.05).
The fractional excretion of sodium (FENa) was significantly
decreased in CsA-treated and placebo animals at all time points,
0 reflecting the low sodium diet (Table 2). CsA caused a progressive
increase in the urinary excretion of AAP that was significant at
days 10, 26 and 36 with maximum excretion at day 26. CsA also
induced a late and significant increase in urinary NAG excretion
at day 26 (Table 2).
Urinary concentrating ability was clearly impaired as indicated
by the progressive and significant increase in urinary volume by
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Fig. 5. Mononuclear cell infiltration detected by ED-i immunostaining in a
CsA -treated animal (A) at day 35 compared to a vehicle-treated control (B)
(200X). C. Graph of time course of macrophage influx over 35 days in
CsA-treated animals compared to vehicle-treated controls.
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Table 1. Serum creatinine, creatinine clearance and urinary protein in placebo and CsA-treated rats after 5, 10, 26 and 35 days of treatment
S mg/dl C. ml!min/100 g Upr0t mgidlig Cr
VH CsA VH CsA VH CsA
Day 5 0.54 0.02 0.62 0.06 0.41 0.02 0.36 0,04 1.92 0.36 1.00 0.21
Day 10
Day 26
0.47 0.01
0.45 0.03
0.59 0.03a
0.80 006b
0.48 0.01
0.46 0.03
0.40 0.02C
0.26 0.021)
1.43 0.15
1.07 0.17
0.69 o.13
0.57 0.09'
Day 35 0.40 0.03 0.85 0.lla 0.55 0.07 0.28 0.07C 0.69 0.13 0.56 0.14
Data are mean SEM.
Abbreviations are: Se,, serum creatinine; Car, clearance of creatinine; Up0, urinary protein; VH, placebo.
aP < 0.005 vs. VII
bp < 0.0005 vs. VH
P < 0.05 vs. VII
Table 2. Fractional excretion of sodium, urinary excretion of alanine aminopeptidase and urinary excretion of N-acetyl f3-D-glucosaminidase in
placebo and CsA-treated rats after 5, 10, 26 and 35 days of treatment
FENa AAPC lUig Cr NAG lUig Cr
VH CsA VH CsAVII CsA
Day 5
Day 10
Day 26
0.10 0.02
0.05 0.01
0.04 0.01
0.09 0.03
0.06 0.02
0.08 0.Ola
35 624 3
24 5 1
48 8
52 6b
05 2O
25 227 2
23 1
26 325 2
34 1C
Day 35 0.02 0.01 0.05 0.02 32 10 68 14 20 2 26 2
Data are mean SEM.
ap < 0.05 vs. VH
b P < 0.005 vs. VH
CJ) < 0.0001 vs. VH
1'a' fractional excretion of sodium; AAP, alanine aminopeptidase; NAG, N-acetyl (3-D-glucosaminidase; VII, placebo.
Table 3. Urinary volume, urinary osmolality and free-water reabsorption in placebo and CsA-treated rats after 5, 10, 26 and 35 days of treatment
UV m1/24 hr Uom mOsm/kg TcW m1/24 hr
VII CsAVII CsA VH CsA
Day 5 13 3 11 1 1789 215 1540 190 52 4 41 3
Day 10
Day 26
11 1
13 1
26 a
22 3b
1932 203
1834 50
654 82C
736 59C
55 3
58 3
24 5C
25 3'
Day 35 14 5 18 4 1407 330 712 187 32 14 16 7
Data are mean SEM.
Abbreviations are: UV, urinary volume; Uoam, urinary osmolality; TcW, free-water reabsorption; VH, placebo.
a P < 0.05 vs. VH
"P < 0.005 vs. VII
p < 0.0005 vs.VH
Table 4. Blood pressure and body weight (mean SEM) in vehicle and
CsA-treated rats after 5, 10, 26, and 35 days
Blood Pressure mm Hg Body weight g
Vehdile CsAVehcile CsA
Day 5 142 7 150 7 356 5 356 7
Day 10 142 7 140 5 340 7 339 13
Day 26 121 7 126 4 372 13 370 11
Day 35 108 6 119 8 393 15 385 13
day 26, and decrease in Uøsm and TcW, which both reached a
nadir at day 26 with partial recovery by day 35 (Table 3).
Discussion
This report describes an animal model of chronic cyclosporine
nephrotoxicity that mimics the histopathological findings found in
chronic CsA-induced injury in humans, especially the arteriolar
hyalinosis and striped cortical interstitial fibrosis. In this model we
found that the interstitial fibrosis and arteriolopathy are preceded
by an acute phase of medullary tubular and interstitial cell
proliferation and macrophage infiltration that accompanies phys-
iologic changes associated with CsA nephrotoxicity including
decreased creatinine clearance, increased creatinine, increased
tubular enzymuria and loss of medullary concentrating ability.
While most of these clinical markers of toxicity stabilize, the
arteriolopathy and interstitial fibrosis are progressive over time
within the confines of our 35-day observation period.
Salt depletion, initially used as a method of increasing "tubu-
loglomerular feedback" [28] via chloride recognition at the mac-
ula densa with subsequent renin secretion by the JG-apparatus
(which is a volume dependent process), has been shown to
accelerate CsA nephropathy [29]. Under these conditions the
nephrotoxicity has been observed by three to four weeks [28]
instead of at three months or longer [30], the earliest time of
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Fig. 8. Immunostaining for osteopontin was increased in a calcification
found in a tubular Cast (400X).
Fig. 7. Immunostaining for osteopontin in the renal cortex at day 35 was
confined to areas of interstitialfibrosis in a CsA -treated animal (A) compared
to a vehicle control animal (B) (bOX). A marked increase in tubular cells
expressing osteopontin is seen in the cortex of the CsA-treated animal in
areas of interstitial fibrosis. No significant cortical osteopontin staining is
present in the control.
observed damage without salt-depletion or supra-therapeutic
doses of CsA. Salt depletion also appears to predispose the
animals to arteriolopathy. Hyaline deposition has been docu-
mented in Wistar-Kyoto hypertensive rats [31], and in rabbit
models of CsA nephropathy [32], but has been difficult to
reproduce in normotensive rat models except with extreme doses
of CsA which produce a lesion seen only ultrastructurally [33].
The details of this important finding are the subject of a separate
report [B. Young et al, companion manuscript, 25]. Since CsA
induced arteriolopathy appears to be a consistent as well as
pathognomonic finding of human chronic CsA-induced injury in
transplants as well as in patients with autoimmune diseases
treated with CsA [4, 5, 7—11], elucidation of the pathogenesis of
the arteriolopathy will be of clinical importance.
The striped interstitial fibrosis which develops in this model is
reproducible [12, 29], and associated with increased deposition of
collagens type I and IV. Procollagen alpha-1(I) messenger RNA
has been documented to be increased in the rat renal cortex with
CsA treatment [34], and type I and type IV mRNA have been
documented to be increased in mice treated with cyclosporine
[35]. However, we also document a component of medullary
fibrosis with increased type IV collagen staining that probably
contributes to the chronic decline in renal function associated
with CsA administration.
The early medullary changes, such as the tubulointerstitial
proliferation and macrophage infiltration, correlated with the
decreased urinary concentrating ability and elevated creatinine.
However, as the tubulointerstitial cell proliferation decreased and
macrophage infiltration subsided, the functional changes stabi-
lized, while cortical interstitial fibrosis progressed. This initial
dissociation between changes in GRF and cortical interstitial
fibrosis has been noted previously [12].
The mechanism for the interstitial fibrosis is unknown. Cyclo-
sporine may induce structural changes due to direct vasoconstric-
tive effects with subsequent ischemia. CsA may also act indirectly
to stimulate other vasoconstrictive factors, such as endothelin [36]
or angiotensin II [37]. Endothelin has been shown to increased in
early CsA-induced injury [38, 39], and endothelin receptor block-
ade inhibits afferent arteriolar vasoconstriction induced by CsA
[40]. The renin-angiotensin II system has also been implicated in
CsA nephropathy, because blockade of the reinin-angiotensin
system by either an angiotensin converting enzyme (ACE) inhib-
itor [41] or with an angiotensin II receptor antagonist [42] reduces
the interstitial fibrosis in CsA nephrotoxicity in rats.
Two components likely involved in the pathogenesis of the
tubulointerstitial fibrosis are cellular proliferation and macro-
phage infiltration. In our study, cellular proliferation (PCNA
positive cells) was first noticed in the medulla, and then pro-
gressed to areas of the fibrosis. The proliferation was both tubular
and interstitial, and is similar to the observations noted by Jackson
et al [43], who found an increased 3H-thymidine uptake in tubular
and interstitial cells in the medulla of animals treated with CsA.
Macrophage accumulation was also prominent in CsA-treated
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rats. Macrophages are known sources of cytokines including
PDGF and TGFI3 which have been posited to have important
roles in cellular proliferation [44] and extracellular matrix depo-
sition [45]. Focal interstitial infiltrates of mononuclear cells are
probably an early finding in interstitial fibrosis induced by CsA in
humans [46], but in transplant recipients have usually been
ascribed to rejection, or called nonspecific. However, mononu-
clear cell infiltrates have been described in kidneys of patients on
CsA with cardiac transplants [7, 47], uveitis [9, 48] and psoriasis
[49]. This suggests that macrophage infiltration may be a conse-
quence of CsA exposure, and supports the hypothesis that mac-
rophages may be important contributors to the interstitial fibrosis
of chronic CsA nephrotoxicity.
The mechanism for the macrophage accumulation in CsA
nephropathy may relate to the increased expression of osteopon-
tin. Osteopontin is an RGD-containing glycoprotein which has
been shown to be chemotactic and adhesive for macrophages in
vitro [50]. Osteopontin can induce a macrophage infiltrate follow-
ing subcutaneous injection into mice [51]. Recently, we have
shown that osteopontin is increased in proximal and distal tubular
cells in several models of glomerular disease and in angiotensin
11-mediated hypertension [23, 52]. Osteopontin expression in
these models correlated with the sites and degree of macrophage
accumulation [23, 52]. Osteopontin was also increased in the
model of CsA nephrotoxicity reported here, and again the sites of
osteopontin expression were co-localized with the sites of macro-
phage accumulation and fibrosis. The mechanism for the Os-
teopontin expression is unknown, but may be due to effects of
angiotensin II [23] or result from nonspecific consequences of
ischemia induced by effects of CsA on the afferent arteriole [53].
Similar changes including vimentin expression, macrophage and T
cell infiltration and diffuse (rather than striped) interstitial fibrosis
have been reported in a model of chronic unilateral renal artery
stenosis [54].
A possible mechanism of chronic CsA nephrotoxicity can be
formulated based on our data. CsA induces acute vascular!
hemodynamic changes, possibly mediated by endothelin, that
cause early ischemic medullary changes, represented clinically by
acute changes in GFR and serum creatinine, and histologically by
medullary tubulointerstitial cell proliferation and macrophage
influx. However, CsA also induces a direct increase in the
intrarenal renin-angiotensin system which probably causes a more
chronic low-grade, ischemic injury to poorly perfused areas of the
cortex and cortico-medullary junction. This stimulates an inflam-
matory response consisting of increased macrophage infiltration,
mild T cell influx and increased osteopontin expression. Os-
teopontin may function as a macrophage chemoattractant and!or
adhesion protein, and may facilitate macrophage localization and
release of growth factors such as TGFp1, resulting in increased
extracellular matrix deposition leading to striped cortical intersti-
tial fibrosis.
We conclude that the salt-depleted rat model of chronic CsA
nephrotoxicity mimics the chronic CsA induced nephropathy seen
in humans and may be useful in studies of the pathophysiology
and toxic effects of chronic CsA administration.
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